Metabolomx Breath Sensor: Modern Tool for Early Cancer Detection

Metabolomx Breath Sensor: Modern Tool for Early Cancer Detection

Headed by Dr. Peter Mazzone of Metabolomx, a diagnostic company that studies early detection of metabolomics signature of cancer merely from exhaled breath, announced its publicized results.

The study was conducted at the Cleveland Clinic breath where samples were drawn from 229 individuals, 92 with biopsy-proven, untreated lung cancer and 137 either at a risk for developing lung cancer or with indeterminate lung nodules. Age, sex, smoking history, and chronic obstructive pulmonary disease of each patient were likewise confirmed. With the use of Metabolomx' first-generation colorimetric sensor array, 80% accuracy in lung cancer was detected, compared to computerized tomography (CT) scan. Further, the first-generation colorimetric sensor array could determine the subtype of lung cancer with accuracy of 90%.

Likewise, the colorimetric sensor array can detect the various patterns of volatile organic compounds present in exhaled breath. In addition, this sensor can give complementary information to computerized tomography and aid clinicians in distinguishing benign from malignant lung nodules.

With the help of Metabolomx' technology, patients can undergo a non-invasive, rapid, inexpensive and early diagnosis of acquired lung cancer and other cancers. Metabolomx is confident that their present generation system is 100 times more accurate and sensitive in detecting breath chemicals.

Posted by George Daniels on Saturday December 17 2011, 1:24 PM EDT. Ref: Dr. Peter Mazzone et al. Link. All trademarks acknowledged. Filed under Health. Comments and Trackbacks closed. Follow responses: RSS 2.0